The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT03551496

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03551496
Other papers using this trial's data
  • Primary results of the SAVAL randomized trial of a paclitaxel-eluting nitinol stent versus percutaneous transluminal angioplasty in infrapopliteal arteries Vascular medicine (London, England), 2023-12 DOI, PubMed 37844137, PMC10693734 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, France, Japan, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03551496. Randomized; single masking; primary purpose treatment. Start 2018-08-31 (actual); primary completion 2022-04-21 (actual). Results posted on 2023-08-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
Acronym
SAVAL
Condition
Critical Limb Ischemia
Intervention (Combination product)
Drug Eluting Stent - Below the Knee
Intervention (Device)
Standard PTA Control Arm
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct03551496
Content hash
df7cf993184b30a85804306c2e3fd8dbde19beddd7a04f28089635461b0658ee